Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting - Zai Lab will highlight potential of ZL-1310 as a promising ...

Dosing underway in Phase 1 clinical trial for ABD-147 (DLL3 ... with high affinity. DLL3 is a protein in the Notch pathway that is critical for the development and regulation of neuroendocrine ...

Delta-like ligand (DLL3) antibody-drug conjugate (ADC) for the treatment of extensive-stage small cell lung cancer (ES-SCLC), will be presented during a poster session at the 2025 American Society ...